MDNAF News and Press, Mandatum Pankki Oyj From 12/12/19

-  MDNA55 achieves up to 5 fold increase in 12 month survival rate in aggressive, chemotherapy resistant glioblastoma when compared to approved therapies TORONTO and HOUSTON , Dec. 12, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX...

Presentation Will Provide Update on Survival Trends in Various Population Subgroups Medicenna to also Present at the LD Micro Investor Conference TORONTO and HOUSTON , Dec. 9, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX: MDNA, OTC...

Medicenna Reports Promising Efficacy in Phase 2b MDNA55 Clinical Trial at the Society for Neuro-Oncology Annual Meeting Canada NewsWire TORONTO and HOUSTON, Nov. 25, 2019 -  Tumor control rate of 82% in recurrent glioblastoma following one treatment with MDNA55 - ...

Results presented at the 3 rd SNO-SCIDOT Joint Conference show 12-month survival benefit of over 111% in patients over-expressing the IL-4 receptor TORONTO and HOUSTON , Nov. 21, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF), a clinical stage imm...

TORONTO and HOUSTON , Nov. 20, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  (" Medicenna " or "the Company ") (TSX: MDNA, OTCQB: MDNAF), a clinical stage Immuno-Oncology company, today announced that it will host a Key Opinion Leader (KOL) call and webcast for the investment ...

Medicenna to Host a Key Opinion Leader Symposium on MDNA55 for Treatment of Recurrent Glioblastoma Canada NewsWire TORONTO and HOUSTON, Nov. 18, 2019 Event to feature renowned leaders in the field of immunotherapy and neuro-oncology TORONTO and HOUSTON , Nov. 18, 2...

Medicenna Announces Presentations on MDNA55 Recurrent Glioblastoma Clinical Trial at the Annual Meeting of the Society of Neuro-Oncology Canada NewsWire TORONTO and HOUSTON, Nov. 14, 2019 Key Opinion Leaders Will Provide Updated Results on Efficacy, Safety and Delivery of ...

Medicenna Therapeutics ( OTCQB:MDNAF ): Q2 GAAP EPS of -C$0.07. More news on: Medicenna Therapeutics Corp., Earnings news and commentary, Consumer stocks news, , Read more ...

Medicenna Reports Second Quarter Fiscal 2020 Financial Results Canada NewsWire TORONTO and HOUSTON, Nov. 5, 2019 TORONTO and HOUSTON , Nov. 5, 2019 /CNW/ - Medicenna Therapeutics Corp. (" Medicenna " or the " Company ") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno...

Medicenna Announces Closing of Public Offering of $6,900,000 Canada NewsWire TORONTO and HOUSTON, Oct. 17, 2019 /NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON , Oct. 17, 2019 /CNW/ - Medicenna Ther...